Carbamazepine Extended-Release Capsules Use in Bipolar Disorder: Efficacy and Safety in Adult Patients

References

• Mitchell PB, Malhi GS: The expanding pharmacopoeia for bipolar disorder. Annu Rev Med 2002; 53:173–188
   Google Scholar
• Strakowski SM, DelBello MP, Adler CM: Comparative efficacy and tolerability of drug treatments for bipolar disorder. CNS Drugs 2001; 15:701–718
   Google Scholar
• McElroy SL, Keck PE Jr: Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry 2000; a48:539–557
   Google Scholar
• Abilify– [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; May 2004
   Google Scholar
• Geodon– [package insert]. New York, NY: Pfizer Inc.; July 2004
   Google Scholar
• Risperdal– [package insert]. Titusville, NJ: Janssen Pharmaceutica Products, LP; December 2003
   Google Scholar
• Seroquel– [package insert]. Wilmington, DE: AstraZeneca LP; April 2003
   Google Scholar
• Kleindienst N, Greil W: Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: Results of the MAP study. Neuropsychobiology 2000; 42\(suppl 1):2–10
   Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159(4 suppl):1–50
   Google Scholar
• Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM: Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58:470–478
   Google Scholar
• Greil W, Ludwig-Mayerhofer W, Erazo N, et al.: Lithium versus carbamazepine in the maintenance treatment of bipolar disorders–a randomised study. J Affect Disord 1997; 43:151–161
   Google Scholar
• Bowden CL, Brugger AM, Swann AC, et al., for the Depakote Mania Study Group: Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994; 271:918–924
   Google Scholar
• Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW: a comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002; 63:1148–1155
   Google Scholar
• Wang PW, Ketter TA, Becker OV, Nowakowska C: New anticonvulsant medication uses in bipolar disorder. CNS Spectr 2003; 8:930–937
   Google Scholar
• Rasgon N: The relationship between polycystic ovary syndrome and antiepileptic drugs: a review of the evidence. J Clin Psychopharmacol 2004; 24:322–334
   Google Scholar
• Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686–1696
   Google Scholar
• Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA: Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160:290–296
   Google Scholar
• Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC: The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002; 63:856–865
   Google Scholar
• Koller EA, Doraiswamy PM: Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002; 22:841–852
   Google Scholar
• Ketter TA, Kalali AH, Weisler RH, for the SPD417 Study Group: A 6-month, multicenter, open-label evaluation of extendedrelease carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004; 65:668–673
   Google Scholar
• Okuma T, Kishimoto A: A history of investigation on the mood stabilizing effect of carbamazepine in Japan. Psychiatry Clin Neurosci 1998; 52:3–12
   Google Scholar
• Keck PE Jr, McElroy SL: Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry 2002; 63\(suppl 4):3–11
   Google Scholar
• Ketter TA, Wang PW, Becker OV, Nowakowska C, Yang YS: The diverse roles of anticonvulsants in bipolar disorders. Ann Clin Psychiatry 2003; 15:95–108
   Google Scholar
• Post RM, Uhde TW, Roy-Byrne PP, Joffe RT: Antidepressant effects of carbamazepine. Am J Psychiatry 1986; 143:29–34
   Google Scholar
• Miller AD, Krauss GL, Hamzeh FM: Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine. Acta Neurol Scand 2004; 109:374–377
   Google Scholar
• Canger R, Altamura AC, Belvedere O, et al.: Conventional vs controlled-release carbamazepine: a multicentre, double-blind, cross-over study. Acta Neurol Scand 1990; 82:9–13
   Google Scholar
• Weisler RH, Kalali AH, Ketter TA, and the SPD417 Study Group: A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004; 65:478–484
   Google Scholar
• Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W: Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997; 73:159–171
   Google Scholar
• Miller AD, Krauss GL, Hamzeh FM: Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine. Acta Neurol Scand 2004; 109:374–377
   Google Scholar
• Mirza WU, Rak IW, Thadani VM, et al.: Six-month evaluation of Carbatrol (extended-release carbamazepine) in complex partial seizures. Neurology 1998; 51:1727–1729
   Google Scholar
• Hogan RE, Garnett WR, Thadani VM: Tolerability and effects on quality of life of twice-daily extended-release carbamazepine in adults with seizure disorders: an open-label, 12- to 36-month continuation study. Clin Ther 2003; 25:2586–2596
   Google Scholar
• McLean A, Browne S, Zhang Y, Slaughter E, Halstenson C, Couch R: The influence of food on the bioavailability of a twicedaily controlled release carbamazepine formulation. J Clin Pharmacol 2001; 41:183–186
   Google Scholar
• Davis JM, Janicak PG, Hogan DM: Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis. Acta Psychiatr Scand 1999; 100:406–417
   Google Scholar
• Dardennes R, Even C, Bange F, Heim A: Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders. A meta-analysis. Br J Psychiatry 1995; 166:378–381
   Google Scholar
• Brown DW, Ketter TA, Crumlish J, Post RM: Carbamazepineinduced increases in total serum cholesterol: clinical and theoretical implications. J Clin Psychopharmacol 1992; 12:431–437
   Google Scholar